@imbria.com
Imbria is a clinical-stage, cardiometabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
JPEG
About
Description
Imbria is a clinical-stage brand focused on developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders. Their mission is to translate their understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options. Imbria offers new treatments for various cardiometabolic disorders including non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction.
Hypertrophic cardiomyopathy is a prevalent genetic cardiomyopathy, affecting 1 in 200 individuals. Stable angina, which can mimic a heart attack, affects over 4% of the adult population and significantly impacts their quality of life. Heart failure is a clinical syndrome characterized by the heart's inability to pump blood sufficiently.
Imbria's pipeline includes Ninerafaxstat, an advanced product candidate for cardiac diseases. By advancing novel treatments and leveraging their expertise in cellular metabolism, Imbria aims to provide effective solutions for patients and physicians alike
Company Type
Privately Held
Company Size
2-10
Year Founded
2018
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories